ORION System Weekly Stock Recommendation: Moderna ($MRNA) – Verdora Excellence Alliance
When many people look at Moderna today, their first reaction is still: “The COVID vaccine company.” And this has been one of Moderna’s biggest challenges over the past few years. During the pandemic, the company generated significant revenue from its COVID vaccine. However, after the peak of the pandemic passed, COVID vaccine demand declined, and Moderna’s revenue fell substantially. Therefore, the market has continued asking: “Beyond COVID vaccines, what else does Moderna have?” By September 18, 2026, this question had begun to receive a clearer answer than before. Because Moderna is attempting to transform from: “A company that generated revenue from one COVID vaccine” into: “An mRNA platform company with respiratory vaccines, cancer therapies, and rare disease treatments.” This is the most important investment logic when analyzing MRNA on September 18. First, the Reality: Moderna Has Not Yet Returned to High Revenue Levels In Q2 2026, Moderna generated total revenue of: $145 million. Compared with: $142 million in the same period last year. There was essentially no meaningful growth. GAAP net loss was approximately: $800 million. Diluted loss per share was: $1.97. Compared with: $2.13 per share loss in the same period last year. Therefore, based only on current financial statements, Moderna is not a company with: Rapid revenue growth and continuously rising profits. Quite the opposite. The company remains in a very typical: Product transition phase. The previous growth engine, COVID vaccines, can no longer support its former revenue scale. Meanwhile, new products have not yet fully reached commercial scale. Therefore, the most important question for MRNA today is not: “How much money will the company make this year?” The more important question is: “Can the company’s product pipeline truly replace the previous revenue engine over the next two to three years?” This Is Also the Biggest Difference Between Biotechnology Companies and Traditional Technology Companies When analyzing NVIDIA, investors can focus on: Revenue. Gross margin. Orders. Data center investment. When analyzing Meta, investors can focus on: Users. Advertising revenue. Cash flow. But biotechnology companies like Moderna cannot be analyzed only by looking at next quarter’s revenue. Because the value of a biotechnology company often comes from: Products that do…